Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 14c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.51), $0.14 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.18 million versus the consensus estimate of $2.65 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook